Immunology of chronic fatigue syndrome

Journal of Chronic Fatigue Syndrome

Volumn 6, Issue 3-4, 2000, Pages 69-107

  Patarca Montero, Roberto ^a   Mark, Timothy ^b   Fletcher, Maryann ^c   Klimas, Nancy G ^c  

^a EM Papper Laboratory of Clinical Immunology ^*  (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokines; Immunoglobulins; Natural killer cells; T cells

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN;

ANTIGEN ANTIBODY COMPLEX; CELL FUNCTION; CHRONIC FATIGUE SYNDROME; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; HUMAN; IMMUNOLOGY; IMMUNOREACTIVITY; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; PHENOTYPE; REVIEW;

EID: 0033804553     PISSN: 10573321     EISSN: None     Source Type: Journal    
DOI: 10.1300/J092v06n03_06     Document Type: Review

References (212)

1. Alterations in central cathecolamines associated with immune responses in adult and aged mice
2. The immune response evokes changes in brain noradrenergic neurons
3. Sympathico-adrenal system activity in a primary immune response
4. The central nervous system and immunity
5. Immunological and neuroendocrine responses of rats to prolonged or repeated stress
6. Chronic variable stress facilitates tumoral growth: Reversal by imipramine administration
7. A prospective study of depression and immune dysregulation in multiple sclerosis
8. Corticotropin-releasing factor and interleukin-1 receptors in the brain-endocrine-immune axis. Role in stress response and infection
9. Stress-induced immune suppression. Role of the autonomic nervous system
10. Widespread activation and consequences of interleukin-1 in the brain
11. Depression and immunity: A meta-analytic review
12. Reduction of immune function in life stress and depression
13. Major depressive disorder, alcoholism, and reduced natural killer cell cytotoxicity
14. Major depressive disorder: Role of age, sex, severity and hospitalization
15. Distal colon motility and clinical parameters in depression
16. Distal colon motility as a predictor of antidepressant response to fenfluramine, imipramine and clomipramine
17. Effects of clonidine on blood pressure, noradrenaline, cortisol, growth hormone and prolactin plasma levels in low and high intestinal tone depressed patients
18. Role of stress in the exacerbation of chronic illness: Effects of clonidine administration on blood pressure, and plasma norepinephrine, cortisol, growth hormone and prolactin concentrations
19. Central neuronal pathways involved in depressive syndrome: Experimental findings
20. Plasma neurotransmitters and cortisol in chronic illness: Role of stress
21. Immunological correlates of the chronic fatigue syndrome
22. The 2H4 (CD45R) antigen is selectively decreased in multiple sclerosis lesions
23. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome
24. Dysregulated expression of soluble immune mediator receptors in a subset of patients with chronic fatigue syndrome: Categorization of patients by immune status
25. Interindividual immune status variation patterns in patients with chronic fatigue syndrome: Association with the tumor necrosis factor system and gender
26. The Sepsis Intervention Group. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome
27. Regulation of cellular and humoral immune responses by T-cell subclasses
28. The characterization and function of human immunoregulatory T lymphocyte subsets
29. Human T lymphocyte subsets. Functional heterogeneity and surface recognition structures
30. Alterations in immunocompetence during stress, bereavement, and depression: Focus on neuroendocrine regulation
31. Immunophenotyping in a multicenter study: The transfusion safety experience
32. Immunologic abnormalities accompanying acute and chronic viral infections
33. Distinctive immune abnormalities in a patient with procainamide-induced lupus and serositis
34. Increased numbers of CD5+ B lymphocytes in schizophrenic patients
35. Immunoregulatory CD4+CD45R+ suppressor/inducer T lymphocyte subsets and impaired cell-mediated immunity in patients with Down's syndrome
36. Aberrant T cell-mediated immunity in untreated schizophrenic patients: Deficient interleukin-2 production
37. Sources of confounding in immunologic data
38. Sex hormones immunity
39. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: Total lymphocyte count fluctutations and diurnal cycle are important
40. Disappearance of CD4 lymphocyte circadian cycles in HIV-infected patients: Early event during asymptomatic infection
41. Assessment of immune mediator expression levels in biological fluids and cells: A critical appraisal
42. Immunological and haematological parameters in patients with chronic fatigue syndrome
43. Validation of biologic markers for use in research on chronic fatigue syndrome
44. Cytokine measurements and interpretation in human disease
45. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection
46. Serologic and immunologic responses in chronic fatigue syndrome with emphasis on the Epstein-Barr virus
47. Chronic Epstein-Barr virus infection
48. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: Elevated anti-early antigen antibodies
49. Epstein-Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis
50. A comprehensive immunological analysis in chronic fatigue syndrome
51. Chronic fatigue syndrome: Clinical condition associated with immune activation
52. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy controls and patients with major depression
53. Immunological abnormalities in patients with chronic fatigue syndrome
54. Immunological abnormalities in the chronic fatigue syndrome
55. Review of laboratory findings for patients with chronic fatigue syndrome
56. Immunologic abnormalities in chronic fatigue syndrome
57. Low natural syndrome: Clinical and immunologic features
58. Gamma globulin therapy for chronic mononucleosis syndrome
59. IgG subclass deficiency and chronic fatigue syndrome
60. Immune responses associated with chronic fatigue syndrome: A case-control study
61. Cryopreservation of peripheral blood mononuclear cells
62. Is there a chronic fatigue syndrome (CFS) dementia
63. The isolation and characterization of the human suppressor inducer T cell subset
64. Immunologic parameters in chronic fatigue syndrome, major depression, and multiple sclerosis
65. Remarkable depression of CD4+2H4+ T cells in severe chronic active Epstein-Barr virus infection
66. T cell regulatory disturbances in the rheumatic diseases
67. Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis
68. Quantitative defect of CD4+2H4+ cells in systemic lupus erythematosus and Sjogren's syndrome
69. Immunologic abnormalities associated with chronic fatigue syndrome
70. A study of the immunology of the chronic fatigue syndrome: Correlation of immunologic markers to health dysfunction
71. Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome
72. Clinical improvement in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation
73. Pathogenesis of insulin-dependent diabetes: A role for activated T lymphocytes
74. Circulating T lymphocytes in Hashimoto's disease: Imbalance of subsets and presence of activated cells
75. Ia+ T cells in new onset Grave's disease
76. Functional property of Ia-positive T cells in peripheral blood from patients with systemic lupus erythematosus
77. Ia-positive T lymphocytes in recently diagnosed idiopathic Addison's disease
78. CD5+ B lymphocytes, polyreactive antibodies and the human B cell repertoire
79. Changes in natural killer cell phenotype in patients with post-viral fatigue syndrome
80. Psychobehavioral and immunological characteristics of adult people with chronic fatigue and patients with chronic fatigue syndrome
81. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome
82. Hormonal influences on stress-induced neutrophil mobilization in health and chronic fatigue syndrome
83. The postviral fatigue syndrome-An analysis of the findings in 50 cases
84. Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr infection
85. Deficient display of CD3 on lymphocytes of patients with chronic fatigue syndrome
86. Correlation between allergy and persistent Epstein-Barr virus infections in chronic active Epstein-Barr virus infected patients
87. Specific allergen-induced Epstein-barr nucler antigen-positive B cells from patients with chronic active Epstein-Barr virus infections
88. Relationships of cognitive difficulties to immune measures, depression and illness burden in chronic fatigue syndrome
89. Elevated apoptotic cell population in patients with chronic fatigue syndrome: The pivotal role of protein kinase RNA
90. The in vitro immunodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with chronic fatigue syndrome
91. Immune function in hronic active Epstein-Barr virus infection
92. Decreased natural killer cell activity is associated with severity of chronic fatigue immune deficiency syndrome
93. In vitro effect of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome
94. Natural killer cells and natural killer cell activity in chronic fatigue syndrome
95. Dysfunction of natural killer activity in a family with chronic fatigue syndrome
96. Chronic fatigue. A prospective clinical and virologic study
97. Immunologic markers in the chronic fatigue syndrome
98. Gamma-interferon and chronic fatigue syndrome
99. CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone
100. Increased (2'-5')-oligo-a synthetase activity in patients with prolonged illness associated with serological evidence of persistent Epstein-barr virus infection
101. Diverse tropism of HBLV (human herpesvirus 6)
102. Stress-associated immune modulation: Relevance to viral infections and chronic fatigue syndrome
103. Decreased nitric oxide-mediated natural killer cell activation in chronic fatigue syndrome
104. Alpha-interferon treatment of patients with chronic fatigue syndrome
105. A novel immunodeficiency: Low NK syndrome (LNKS)
106. Mizukoshi Acting mechaanisms of Lentinan in humans II Enhancement of non-specific cell-mediated cytotoxicity as an interferon induced response
107. Naloxone-reversible monocyte dysfunction in patients with chronic fatigue syndrome
108. Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome
109. Eosinophil cationic protein serum levels and allergy in chronic fatigue syndrome
110. Influence of immediate hypersensitivity skin reaction on delayed reactions in patients with chronic fatigue syndrome
111. Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome
112. IgE concentrations in chronic fatigue syndrome
113. Rhinitis symptoms in chronic fatigue syndrome
114. Chronic fatigue syndrome: Identification of distinct subgroups on the basis of allergy and psychologic variables
115. Chronic fatigue syndrome: An atopic state
116. Chronic fatigue syndrome: An immunological perspective
117. Susceptibility to immunologically mediated fatigue in C57BL/6 versus Balb/c mice
118. Gulf War syndrome: Is it due to a systemic shift in cytokine balance towards a Th2 profile?
119. Interferon-induced proteins are elevated in blood samples of patients with chemically or virally induced chronic fatigue syndrome
120. Interleukin-1 and interleukin-1 antagonism
121. Interleukin-1: Biology, pathophysiology, and clinical prospects
122. Dysregulated expression of tumor necrosis factor in the chronic fatigue immune dysfunction syndrome: Interrelations with cellular sources and patterns of soluble immune mediator expression
123. Serum levels of lymphokines and soluble cellular receptors in primary EBV infection and in patients with chronic fatigue syndrome
124. Chronic fatigue syndrome-a controlled cross sectional study
125. Production of interleukin-1 by peripheral blood mononuclear cells in patients with chronic fatigue syndrome
126. Circulating lymphokine levels in the chronic fatigue syndrome
127. Nervous system-immune system communication
128. Corticotropin-releasing factor-producing neurons in the RT activated by interleukin-1
129. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones
130. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor
131. Release of multiple hormones by a direct action of interleukin-1 on pituitary cells
132. 2 release to suppress pulsatile release of luteinizing hormone but not follicle-stimulating hormone
133. Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep
134. Chronic fatigue syndrome: A working cased definition
135. Nonrestorative sleep and symptoms after a febrile illness in patients with fibrosis and chronic fatigue syndrome
136. Secretion of S-100 from rat C6 glioma cells
137. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down's syndrome and Alzheimer's disease
138. Modulation of endothelial cell function by different molecular species of interleukin-1
139. Interleukin-1 decreases renal sodium reabsorption: Possible mechanisms of endotoxin-induced natriuresis
140. Interleukin-1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness
141. Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome
142. Cachectin (tumor necrosis factor). A macrophage hormone governing cellular metabolism and inflammatory response
143. A novel form of TNF-cachectin in a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF
144. In vitro evidence for a dual role of tumor necrosis factor in human immunodeficiency virus type 1 encephalopathy
145. Elevated levels of tumor necrosis factor alpha in postdialysis fatigue
146. Interleukin-1 and tumor necrosis factor: Effector cytokines in autoimmune diseases
147. Interleukin-2: A class of T cell growth factor
148. Recent advances in the understanding of the biochemistry and clinical pharmacology of interelukin-2
149. Selective in vitro growth of T lymphocytes from normal human bone marrows
150. Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes
151. Expression of Tac antigen on activated normal human B cells
152. Interleukin-2 and the chronic fatigue syndrome
153. Soluble interleukin-2 receptor: Detection and potential role in organ transplantation
154. Serum interleukin-2 receptor: Clinical and biological implications
155. B-cell stimulatory factor-1/interleukin-4
156. Generation and analysis of interlekin-4 deficient mice
157. Serum neopterin and interleukin-6 levels in chronic fatigue syndrome
158. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome
159. The interleukins
160. Interleukin-6: An overview
161. Cytokine dysregulation in the post-Q-fever syndrome
162. Interferon and myalgic encephalomyelitis
163. Myalgic encephalomyelitis and alpha-interferon
164. Fatigue: Definitions, mechanisms, and paradigms for study
165. Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha
166. Pattern of neurobehavioral deficits with interferon alpha therapy for leukemia
167. Immune system activation and fatigue during treadmill running: Role of interferon
168. Characterization of the gamma interferon-mediated induction of antigen-presenting ability in P388D cells
169. In vitro interactions of purified cloned human interferons on NK cells: Enhanced activation
170. Interferon inhibits the suppressor T cell response of delayed hypersensitivity
171. Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome
172. Neopterin: An early marker of development of pre-AIDS conditions in HIV-seropositive individuals
173. Pteridines and neuroimmune function and pathology
174. Nitric oxide synthase and antimicrobial armature of human macrophages
175. Nitric oxide and AIDS dementia
176. Effect of neopterin and 7,8-dihydroneopterin on tumor necrosis factor-alpha induced programmed cell death
177. Physical symptoms of chronic fatigue syndrome are exacerbated by the stress of Hurricane Andrew
178. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms
179. Decreased serum tryptophan in patients with cancer cachexia correlates with increased serum neopterin
180. Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children
181. Biochemical studies on AIDS dementia complex-possible contribution of quinolinic acid during brain damage
182. Increased neopterin levels in brains of patients with human immunodeficiency virus type 1 infection
183. Pteridines in plasma and in cells of peripheral blood tumor patients
184. Quantitative detection of brain aberrations in human immunodeficiency virus type 1-infected individuals by magnetic resonance imaging
185. Chronic illness characterized by fatigue, neurologic and immunologic disorders and active human herpesvirus 6 type infection
186. Immunological reason for chronic ill health after infectious mononucleosis
187. Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis)
188. Chronic fatigue syndrome: Evaluation of a 30-criteriascore and correlation with immune activation
189. IgG1 subclass deficiency in patients with chronic fatigue syndrome
190. Antibody response to Epstein-Barr virus antigens in patients with chronic viral infection
191. Sporadic postinfectious neuromyasthenia
192. Immunoglobulin subclass abnormalities in patients with chronic fatigue syndrome
193. IgG subclass deficiencies in chronic fatigue syndrome
194. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome
195. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome
196. Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents
197. Intravenous immunoglobulin treatment for the chronic fatigue syndrome
198. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome
199. Immunoglobulin subclass levels in chronic fatigue syndrome
200. Autoantibodies to nuclear antigens in chronic fatigue syndrome
201. Fatigue syndromes and the aetiology of autoimmune disease
202. High frequency of autoantibodies in patients with chronic fatigue syndrome
203. Association between HLA class II antigens and the chronic fatigue immune dysfunction syndrome
204. Liver extract-folic acid-cyanocobalamin vs. placebo for chronic fatigue syndrome
205. Clinical laboratory test findings in patients with chronic fatigue syndrome
206. Incidence of antinuclear antibodies in Japanese patients with chronic fatigue syndrome
207. Thyroiditis and 'chronic infectious mononucleosis.'
208. Antimuscle and anti-CNS circulating antibodies in chronic fatigue syndrome
209. Psychological stress and susceptibility to the common cold
210. Stress-associated immune modulation: Implications for infectious diseases?